Switching from Propranolol 40mg to Bisoprolol
You can switch directly from propranolol 40mg daily to bisoprolol 2.5mg daily without tapering or overlap, monitoring heart rate and blood pressure within the first week.
Dose Conversion and Switching Method
The conversion between propranolol and bisoprolol is not based on strict equipotency ratios, as these beta-blockers differ significantly in their pharmacologic properties. Propranolol is a nonselective beta-blocker with a short half-life requiring twice-daily dosing, while bisoprolol is a cardioselective (beta-1 selective) agent with a longer half-life allowing once-daily administration 1, 2.
For propranolol 40mg daily, the recommended starting dose of bisoprolol is 2.5mg once daily, which can be titrated up to 5-10mg daily based on clinical response 1, 2. This conservative starting approach accounts for the longer half-life of bisoprolol and allows assessment of individual patient response.
Switching Strategy
Direct switch without tapering: Stop propranolol and start bisoprolol the next day. Unlike abrupt cessation of beta-blockers in patients with coronary artery disease (where tapering is critical to avoid rebound phenomena), switching between beta-blockers for hypertension or other indications can typically be done directly 3.
However, there are important caveats:
If the patient has coronary artery disease or a history of myocardial infarction, consider a brief overlap or more cautious approach, as abrupt beta-blocker withdrawal can precipitate angina, arrhythmias, or even myocardial infarction 3.
Monitor closely in the first week for bradycardia, hypotension, or symptoms of inadequate beta-blockade (if treating conditions like thyrotoxicosis or tachyarrhythmias).
Clinical Context Matters
The reason for switching influences the approach:
For hypertension: Direct switch is appropriate. Bisoprolol 2.5mg once daily is the starting dose, with titration to 5-10mg as needed for blood pressure control 1, 2.
For heart failure: If switching in a patient with heart failure with reduced ejection fraction (HFrEF), bisoprolol is guideline-recommended and should be started at 2.5mg daily, then uptitrated slowly (doubling every 2-4 weeks) to a target of 10mg daily 4. The switch should be done carefully with close monitoring, as beta-blockers can precipitate acute decompensation 3.
For specific conditions requiring nonselective blockade (e.g., long QT syndrome, thyrotoxicosis): Be cautious. Case reports suggest that switching from propranolol to bisoprolol in long QT syndrome patients resulted in loss of arrhythmia control and syncope 5. In thyrotoxicosis, propranolol has additional benefits (inhibiting T4 to T3 conversion) that bisoprolol lacks 6. In these situations, propranolol should generally not be switched to bisoprolol.
Practical Monitoring
- Check heart rate and blood pressure within 3-7 days of the switch
- Assess for symptoms of inadequate beta-blockade (palpitations, tremor if treating thyrotoxicosis) or excessive blockade (fatigue, dizziness, bradycardia)
- Titrate bisoprolol dose based on clinical response: if heart rate remains elevated or blood pressure uncontrolled, increase to 5mg, then 10mg as tolerated
- Avoid abrupt discontinuation of bisoprolol once established, as with all beta-blockers 3
Key Contraindications and Warnings
Both drugs share similar contraindications, but bisoprolol's beta-1 selectivity offers theoretical advantages in patients with:
- Bronchospastic disease: Bisoprolol may be used cautiously where propranolol is contraindicated, though a beta-2 agonist should be available 3
- Peripheral vascular disease: Beta-1 selectivity may reduce risk of exacerbating symptoms
Absolute contraindications to bisoprolol include second- or third-degree heart block, decompensated heart failure, cardiogenic shock, and severe bradycardia 3.
Common Pitfalls
- Don't assume dose equivalence: 40mg propranolol does not equal a specific bisoprolol dose; start conservatively at 2.5mg
- Don't taper propranolol in routine hypertension cases: Direct switch is safe and appropriate
- Do taper if coronary disease is present: Consider brief overlap or gradual transition
- Don't switch in long QT syndrome or thyrotoxicosis without specialist input: Propranolol's nonselective properties may be therapeutically necessary 5, 6